About Pyros Pharma
Pyros Pharma is a company based in New York (United States) founded in 2017 was acquired by Bora Pharmaceuticals in October 2024. Pyros Pharma has raised $6.39 million across 2 funding rounds from investors including Bora Pharmaceuticals. Pyros Pharma offers products and services including VIGAFYDE™ (vigabatrin) and Specialty Pharmaceuticals.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pyros Pharmaceuticals, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.39 M (USD)
in 2 rounds
-
Latest Funding Round
$450 K (USD), Series A
Apr 04, 2022
- Investors
-
Employee Count
Not available
-
Acquired by
Bora Pharmaceuticals
(Oct 25, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pyros Pharma
Pyros Pharma offers a comprehensive portfolio of products and services, including VIGAFYDE™ (vigabatrin) and Specialty Pharmaceuticals.
A ready-to-use oral solution is provided for the treatment of infantile spasms
Enhanced pharmaceuticals are developed for rare diseases to improve treatment standards
People of Pyros Pharma
Unlock access to complete
Sales and Marketing
2 people
Leadership Team
1 people
Labeling Team
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of Pyros Pharma
Pyros Pharma has successfully raised a total of $6.39M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $450 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pyros Pharma
Pyros Pharma has secured backing from 1 investor. Prominent investors backing the company include Bora Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Traditional pharma company manufacturing and marketing a range of pharmaceutical products
|
Locked | Locked | Locked |
Investor details for Pyros Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pyros Pharma
Investment portfolio details for Pyros Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pyros Pharma
Detailed financials for Pyros Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pyros Pharma Comparisons
Peer comparison for Pyros Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pyros Pharma
Detailed competitors of Pyros Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pyros Pharma
Complete news archive for Pyros Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pyros Pharma
Pyros Pharma was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Pyros Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Pyros Pharma is a funded company, having raised a total of $6.39M across 2 funding rounds to date.
Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for rare diseases, particularly those affecting infants and young children. The company is driven by a mission to elevate the standard of care for infantile spasms and is committed to making a meaningful difference in the lives of patients and families.
Pyros Pharma offers VIGAFYDE™ (vigabatrin) and Specialty Pharmaceuticals.
Pyros Pharma has 1 investor. Key investors include Bora Pharmaceuticals.